Driehaus Capital Management LLC Buys New Shares in Lifevantage Corporation $LFVN

Key Points

• Driehaus Capital Management LLC invested approximately $6.70 million in Lifevantage Corporation, acquiring 459,619 shares in the first quarter of this year.
• Lifevantage recently declared a quarterly dividend of $0.045 per share, resulting in an annualized yield of 1.4%, set to be paid on September 16th.
• The stock has a market capitalization of $164.90 million and has shown significant volatility, with a twelve-month range between $7.09 and $27.38.

Driehaus Capital Management LLC bought a new position in shares of Lifevantage Corporation (NASDAQ:LFVN - Free Report) during the first quarter, according to its most recent Form 13F filing with the SEC. The fund bought 459,619 shares of the company's stock, valued at approximately $6,701,000. Driehaus Capital Management LLC owned about 3.65% of Lifevantage at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of the business. Brown Advisory Inc. bought a new stake in shares of Lifevantage in the first quarter worth $150,000. Cannon Global Investment Management LLC bought a new stake in shares of Lifevantage in the 1st quarter valued at about $156,000. State of Wyoming acquired a new stake in shares of Lifevantage in the first quarter valued at about $173,000. XTX Topco Ltd bought a new position in shares of Lifevantage during the first quarter worth about $186,000. Finally, Cambridge Investment Research Advisors Inc. raised its position in shares of Lifevantage by 23.2% during the first quarter. Cambridge Investment Research Advisors Inc. now owns 12,867 shares of the company's stock worth $188,000 after acquiring an additional 2,421 shares during the last quarter. Institutional investors own 35.32% of the company's stock.

Insider Buying and Selling

In other news, CFO Carl Aure sold 2,746 shares of Lifevantage stock in a transaction dated Tuesday, July 1st. The stock was sold at an average price of $13.39, for a total value of $36,768.94. Following the completion of the transaction, the chief financial officer directly owned 133,303 shares of the company's stock, valued at approximately $1,784,927.17. This trade represents a 2.02% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 20.65% of the company's stock.

Lifevantage Trading Down 1.4%

LFVN stock traded down $0.20 during trading on Thursday, hitting $13.38. The company had a trading volume of 108,292 shares, compared to its average volume of 191,335. The stock has a market cap of $168.39 million, a PE ratio of 19.38 and a beta of 0.39. The business has a 50-day moving average of $13.13 and a 200-day moving average of $13.75. Lifevantage Corporation has a one year low of $8.17 and a one year high of $27.38.

Lifevantage Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 16th. Investors of record on Monday, September 8th will be issued a $0.045 dividend. The ex-dividend date is Monday, September 8th. This represents a $0.18 annualized dividend and a yield of 1.3%. Lifevantage's payout ratio is presently 26.09%.

Lifevantage Profile

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix.